[Federal Register Volume 67, Number 198 (Friday, October 11, 2002)]
[Notices]
[Pages 63433-63434]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-25953]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 02186]


Oral Vaccine Institute; Notice of Award of Funds

A. Purpose

    The Centers for Disease Control and Prevention (CDC) announces the 
award of fiscal year (FY) 2002 funds for a grant for Oral Vaccine 
Institute (OVI) research on liposome-based delivery systems for oral or 
nasal vaccination. This program addresses the ``Healthy People 2010'' 
focus areas of Immunization and Infectious Diseases; Maternal, Infant 
and Child Health; Medical Product Safety; and Sexually Transmitted 
Diseases.
    The purpose of the program is to develop a platform of liposome 
constructs containing vaccine antigens that can immunize through the 
oral or nasal routes, rather than via parenteral injection with 
conventional needle and syringes.

B. Eligible Applicant

    This grant is to be awarded to the Oral Vaccine Institute, which is 
affiliated with Oral Vaccine Technologies, Inc. (OVT), a for-profit 
company based in Las Vegas, Nevada and incorporated in Nevada. OVT owns 
several patents currently issued by the U.S. Patent office. They have 
assembled a team of scientists with considerable expertise in the areas 
of liposome development, vaccine development and mucosal immunity. OVT 
has executed an agreement allowing the Oral Vaccine Institute the right 
to use its intellectual property that is set forth and described in its 
Executive Summary for certain research purposes.
    BioMedical Research Models, Inc. (BRM) is under contract to provide 
certain laboratory facility capabilities and personnel to accomplish 
the mission of the Oral Vaccine Institute. The facility is fully 
prepared to

[[Page 63434]]

administer and assist the proposed animal-based studies.
    Acting in concert with these three organizations (OVI, OVT and 
BRM), and their scientific staffs and consultants, the Institute will 
develop platform technologies that could significantly impact the 
response to a bioterrorism attack.
    Justification: This grant is awarded sole source by virtue of 
Congressional earmark evidenced in the following records of Congress: 
Senate-House Conference Committee, Calendar No. 193, 107th Congress 
Report-Senate; assessable in pages 88-89 of 229 of pdf document: http://frwebgate.access.gpo.gov/cgi-bin/grtdoc.cgi?dbname=107_cong_reports&docid=f:hr342.107.pdf

    Note: Title 2 United States Code section 1611 states that an 
organization described in section 501(c)(4) of the Internal Revenue 
Code that engages in lobbying activities is not eligible to receive 
Federal funds constituting an award, grant or loan.

C. Funds

    Approximately $1.2 million is being awarded in FY 2002. It is 
expected that the award will begin on or before September 15, 2002, and 
will be made for a 12 month budget period within a project period of 
one year. The funding estimate may change.

D. Where To Obtain Additional Information

    This and other CDC announcements can be found on the CDC home page 
Internet address--http://www.cdc.gov. Click on ``Funding'' then 
``Grants and Cooperative Agreements.''
    For business management assistance contact: Peaches Brown, Grants 
Management Specialist, Grants Management Branch, Procurement and Grants 
Office, Centers for Disease Control and Prevention, 2920 Brandywine 
Road, Room 3000, Atlanta, GA 30341-4146, Telephone: 770-488-2738, e-
mail address: [email protected].
    For program technical assistance, contact: Dr. Bruce Weniger, 
Vaccine Safety and Development Activity, National Immunization Program, 
Centers for Disease Control and Prevention, 1600 Clifton Road mailstop 
E-61, Atlanta, GA 30333, Telehone: 404-639-8779, e-mail address: 
[email protected].
    For program administrative assistance, contact: Sharon Holmes, 
Program Analyst, Vaccine Safety and Development Activity, National 
Immunization Program, Centers for Disease Control and Prevention, 1600 
Clifton Road mailstop E-61, Atlanta, GA 30333, Telephone: 404-639-8582, 
e-mail address: [email protected].

    Dated: October 4, 2002.
Sandra R. Manning,
Director, Procurement and Grants Office, Centers for Disease Control 
and Prevention.
[FR Doc. 02-25953 Filed 10-10-02; 8:45 am]
BILLING CODE 4163-18-P